Joanna Bandola-Simon
Research Subjects
Research Interests
Joanna Bandola-Simon has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Paul A. Roche
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
7 shared publications Sebastian Brenner
Department of Pediatrics, University Clinic Dresden, Dresden, Germany
3 shared publicationsSebastian Thieme
Department of Pediatrics, University Clinic Dresden, Dresden, Germany
3 shared publications- Andreas Dahl
DRESDEN-concept Genome Center (DcGC), Center for Molecular and Cellular Bioengineering (CMCB) Technology Platform, TUD Dresden University of Technology, 01062 Dresden, Germany
2 shared publications Cornelia Richter
Department of Pediatrics, University Clinic Dresden, Dresden, Germany
2 shared publications- Cornelia Richter
Radiation and Environmental Protection Department, Gesellschaft für Anlagen- und Reaktorsicherheit (GRS) gGmbH, Köln, Germany
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
MHC Class II and Beyond: Complex Role of CD74 in Cancer
Invariant chain, also known as CD74 when expressed on the plasma membrane, is classically recognized for its role in Major Histocompatibility Complex class II molecule assembly, trafficking, and peptide loading in professional antigen presenting cells. However, recent studies implicate CD74 as a broader regulator of tumor–immune interactions, modulating antigen presentation, cytokine signaling, and immune evasion across diverse cancers. This review synthesizes emerging evidence that CD74 functions as a “master regulator” of antigen presentation in cancer, integrating its canonical chaperone role with its noncanonical role in transcription regulation and in signaling via macrophage migration inhibitory factor. We explore how tumor microenvironmental contexts redefine CD74 biology, influencing antitumor immunity and therapeutic outcomes.
Top Cited PapersOpen AccessMHC Class II and Beyond: Complex Role of CD74 in Cancer
Invariant chain, also known as CD74 when expressed on the plasma membrane, is classically recognized for its role in Major Histocompatibility Complex class II molecule assembly, trafficking, and peptide loading in professional antigen presenting cells. However, recent studies implicate CD74 as a broader regulator of tumor–immune interactions, modulating antigen presentation, cytokine signaling, and immune evasion across diverse cancers. This review synthesizes emerging evidence that CD74 functions as a “master regulator” of antigen presentation in cancer, integrating its canonical chaperone role with its noncanonical role in transcription regulation and in signaling via macrophage migration inhibitory factor. We explore how tumor microenvironmental contexts redefine CD74 biology, influencing antitumor immunity and therapeutic outcomes.
- Open Access
- 17 December 2025
- Published by MDPI AG in Preprints.org
MHC Class II and Beyond: Complex Role of CD74 in Cancer
Invariant chain, also known as CD74 when expressed on the plasma membrane, is classically recognized for its role in Major Histocompatibility Complex class II molecule assembly, trafficking, and peptide loading in professional antigen presenting cells. However, recent studies implicate CD74 as a broader regulator of tumor-immune interactions, modulating antigen presentation, cytokine signaling, and immune evasion across diverse cancers. This review synthesizes emerging evidence that CD74 functions as a “master regulator” of antigen presentation in cancer, integrating its canonical chaperone role with its noncanonical role in transcription regulation and in signaling via macrophage migration inhibitory factor. We explore how tumor microenvironmental contexts redefine CD74 biology, influencing antitumor immunity and therapeutic outcomes.
- 17 December 2025
- Published by MDPI AG in Preprints.org
Open AccessMHC Class II and Beyond: Complex Role of CD74 in Cancer
Invariant chain, also known as CD74 when expressed on the plasma membrane, is classically recognized for its role in Major Histocompatibility Complex class II molecule assembly, trafficking, and peptide loading in professional antigen presenting cells. However, recent studies implicate CD74 as a broader regulator of tumor-immune interactions, modulating antigen presentation, cytokine signaling, and immune evasion across diverse cancers. This review synthesizes emerging evidence that CD74 functions as a “master regulator” of antigen presentation in cancer, integrating its canonical chaperone role with its noncanonical role in transcription regulation and in signaling via macrophage migration inhibitory factor. We explore how tumor microenvironmental contexts redefine CD74 biology, influencing antitumor immunity and therapeutic outcomes.
- 17 April 2023
- Published by Elsevier in Current Opinion in Immunology
- Vol. 82, 102325
Regulation of MHC class II and CD86 expression by March-I in immunity and disease
- 17 April 2023
- Published by Elsevier in Current Opinion in Immunology
- Vol. 82, 102325
Regulation of MHC class II and CD86 expression by March-I in immunity and disease
- Open Access
- 14 December 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (3) , 494-504
Ubiquitination of MHC Class II by March-I Regulates Dendritic Cell Fitness
The expression and turnover of Ag-specific peptide–MHC class II (pMHC-II) on the surface of dendritic cells (DCs) is essential for their ability to efficiently activate CD4 T cells. Ubiquitination of pMHC-II by the E3 ubiquitin ligase March-I regulates surface expression and survival of pMHC-II in DCs. We now show that despite their high levels of surface pMHC-II, MHC class II (MHC-II) ubiquitination–deficient mouse DCs are functionally defective; they are poor stimulators of naive CD4 T cells and secrete IL-12 in response to LPS stimulation poorly. MHC-II ubiquitination–mutant DC defects are cell intrinsic, and single-cell RNA sequencing demonstrates that these DCs have an altered gene expression signature as compared with wild-type DCs. Curiously, these functional and gene transcription defects are reversed by activating the DCs with LPS. These results show that dysregulation of MHC-II turnover suppresses DC development and function.
- 14 December 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (3) , 494-504
Open AccessUbiquitination of MHC Class II by March-I Regulates Dendritic Cell Fitness
The expression and turnover of Ag-specific peptide–MHC class II (pMHC-II) on the surface of dendritic cells (DCs) is essential for their ability to efficiently activate CD4 T cells. Ubiquitination of pMHC-II by the E3 ubiquitin ligase March-I regulates surface expression and survival of pMHC-II in DCs. We now show that despite their high levels of surface pMHC-II, MHC class II (MHC-II) ubiquitination–deficient mouse DCs are functionally defective; they are poor stimulators of naive CD4 T cells and secrete IL-12 in response to LPS stimulation poorly. MHC-II ubiquitination–mutant DC defects are cell intrinsic, and single-cell RNA sequencing demonstrates that these DCs have an altered gene expression signature as compared with wild-type DCs. Curiously, these functional and gene transcription defects are reversed by activating the DCs with LPS. These results show that dysregulation of MHC-II turnover suppresses DC development and function.
- 1 September 2019
- Published by Elsevier in Molecular Immunology
- Vol. 113, 31-37
Dysfunction of antigen processing and presentation by dendritic cells in cancer
- 1 September 2019
- Published by Elsevier in Molecular Immunology
- Vol. 113, 31-37
Dysfunction of antigen processing and presentation by dendritic cells in cancer
- Open Access
- 1 May 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 202 (1_Suppleme) , 135.16
Dendritic cells dysfunction in tumor-draining lymph nodes
An effective anti-tumor response requires activation of both CD4 helper T cells (through MHC class II) and CD8 cytotoxic T cells (through MHC class I). Activation of tumor-specific CD4 and CD8 T cells depends on tumor antigen presentation by DCs. However, it is known that the tumor microenvironment largely suppresses immune responses. The focus of our study is to characterize the functional status of DCs in tumor-draining lymph nodes and to identify the mechanisms that lead to defective MHC class II presentation of tumor antigens. We injected either B16-F10 melanoma or MB49 bladder cancer adenocarcinoma cells into the flank of mice and isolated DCs from both tumor-draining lymph node (TDLN) and non-draining lymph nodes (NDLN) as our model system. Cross-presentation of OVA to OVA-specific CD8 T cells was not suppressed in TDLN in comparison to the NDLN either in vivo and ex vivo. However, both in vivo and ex vivo CD4 T cell activation by DCs from TDLNs was defective. Subset analysis revealed that both migratory and resident CD8-positive and CD8-negative DCs in TDLN show a less mature phenotype as compared to their counterparts isolated from NDLN. Examination of antigen uptake and processing also showed defects in DCs in TDLN. RNA-seq revealed many differences in gene expression between both resident and migratory DCs isolated from TDLN and NDLN. Characterized phenotypical and functional differences, confirmed by gene expression studies, may explain the dysfunction of DCs in tumor-bearing mice. Further analysis should enable moving towards “correcting” DC defects that would allow proper CD4 T cell priming to provide help to anti-tumor CD8 T cells.
- 1 May 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 202 (1_Suppleme) , 135.16
Open AccessDendritic cells dysfunction in tumor-draining lymph nodes
An effective anti-tumor response requires activation of both CD4 helper T cells (through MHC class II) and CD8 cytotoxic T cells (through MHC class I). Activation of tumor-specific CD4 and CD8 T cells depends on tumor antigen presentation by DCs. However, it is known that the tumor microenvironment largely suppresses immune responses. The focus of our study is to characterize the functional status of DCs in tumor-draining lymph nodes and to identify the mechanisms that lead to defective MHC class II presentation of tumor antigens. We injected either B16-F10 melanoma or MB49 bladder cancer adenocarcinoma cells into the flank of mice and isolated DCs from both tumor-draining lymph node (TDLN) and non-draining lymph nodes (NDLN) as our model system. Cross-presentation of OVA to OVA-specific CD8 T cells was not suppressed in TDLN in comparison to the NDLN either in vivo and ex vivo. However, both in vivo and ex vivo CD4 T cell activation by DCs from TDLNs was defective. Subset analysis revealed that both migratory and resident CD8-positive and CD8-negative DCs in TDLN show a less mature phenotype as compared to their counterparts isolated from NDLN. Examination of antigen uptake and processing also showed defects in DCs in TDLN. RNA-seq revealed many differences in gene expression between both resident and migratory DCs isolated from TDLN and NDLN. Characterized phenotypical and functional differences, confirmed by gene expression studies, may explain the dysfunction of DCs in tumor-bearing mice. Further analysis should enable moving towards “correcting” DC defects that would allow proper CD4 T cell priming to provide help to anti-tumor CD8 T cells.
- Open Access
- 24 October 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (10) , e0204898
The E3 ubiquitin ligase MARCH1 regulates glucose-tolerance and lipid storage in a sex-specific manner
Type 2 diabetes is typified by insulin-resistance in adipose tissue, skeletal muscle, and liver, leading to chronic hyperglycemia. Additionally, obesity and type 2 diabetes are characterized by chronic low-grade inflammation. Membrane-associated RING-CH-1 (MARCH1) is an E3 ubiquitin ligase best known for suppression of antigen presentation by dendritic and B cells. MARCH1 was recently found to negatively regulate the cell surface levels of the insulin receptor via ubiquitination. This, in turn, impaired insulin sensitivity in mouse models. Here, we report that MARCH1-deficient (knockout; KO) female mice exhibit excessive weight gain and excessive visceral adiposity when reared on standard chow diet, without increased inflammatory cell infiltration of adipose tissue. By contrast, male MARCH1 KO mice had similar weight gain and visceral adiposity to wildtype (WT) male mice. MARCH1 KO mice of both sexes were more glucose tolerant than WT mice. The levels of insulin receptor were generally higher in insulin-responsive tissues (especially the liver) from female MARCH1 KO mice compared to males, with the potential to account in part for the differences between male and female MARCH1 KO mice. We also explored a potential role for MARCH1 in human type 2 diabetes risk through genetic association testing in publicly-available datasets, and found evidence suggestive of association. Collectively, our data indicate an additional link between immune function and diabetes, specifically implicating MARCH1 as a regulator of lipid metabolism and glucose tolerance, whose function is modified by sex-specific factors.
- 24 October 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (10) , e0204898
Open AccessThe E3 ubiquitin ligase MARCH1 regulates glucose-tolerance and lipid storage in a sex-specific manner
Type 2 diabetes is typified by insulin-resistance in adipose tissue, skeletal muscle, and liver, leading to chronic hyperglycemia. Additionally, obesity and type 2 diabetes are characterized by chronic low-grade inflammation. Membrane-associated RING-CH-1 (MARCH1) is an E3 ubiquitin ligase best known for suppression of antigen presentation by dendritic and B cells. MARCH1 was recently found to negatively regulate the cell surface levels of the insulin receptor via ubiquitination. This, in turn, impaired insulin sensitivity in mouse models. Here, we report that MARCH1-deficient (knockout; KO) female mice exhibit excessive weight gain and excessive visceral adiposity when reared on standard chow diet, without increased inflammatory cell infiltration of adipose tissue. By contrast, male MARCH1 KO mice had similar weight gain and visceral adiposity to wildtype (WT) male mice. MARCH1 KO mice of both sexes were more glucose tolerant than WT mice. The levels of insulin receptor were generally higher in insulin-responsive tissues (especially the liver) from female MARCH1 KO mice compared to males, with the potential to account in part for the differences between male and female MARCH1 KO mice. We also explored a potential role for MARCH1 in human type 2 diabetes risk through genetic association testing in publicly-available datasets, and found evidence suggestive of association. Collectively, our data indicate an additional link between immune function and diabetes, specifically implicating MARCH1 as a regulator of lipid metabolism and glucose tolerance, whose function is modified by sex-specific factors.
- Open Access
- 1 March 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (11) , 3904-3912
Ubiquitin-conjugating enzyme E2 D1 (Ube2D1) mediates lysine-independent ubiquitination of the E3 ubiquitin ligase March-I
- 1 March 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (11) , 3904-3912
Open AccessUbiquitin-conjugating enzyme E2 D1 (Ube2D1) mediates lysine-independent ubiquitination of the E3 ubiquitin ligase March-I
- Open Access
- 17 August 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 981
Neurotrophin Receptor p75NTR Regulates Immune Function of Plasmacytoid Dendritic Cells
Plasmacytoid dendritic cells (pDCs) regulate innate and adaptive immunity. Neurotrophins and their receptors control the function of neuronal tissue. In addition, they have been demonstrated to be part of the immune response but little is known about the effector immune cells involved. We report, for the first time, the expression and immune-regulatory function of the low affinity neurotrophin receptor p75NTR by the antigen-presenting plasmacytoid dendritic cells (pDCs), mediated by Toll-like receptor (TLR) 9 activation and differential phosphorylation of interferon regulatory factor (IRF) 3 and 7. The modulation of p75NTR on pDCs significantly influences disease progression of asthma in an ovalbumin-induced mouse model mediated by the TLR9 signaling pathway. p75NTR activation of pDCs from patients with asthma increased allergen-specific T cell proliferation and cytokine secretion in NGF concentration dependent manner. Further, p75NTR activation of pDCs delayed the onset of autoimmune diabetes in RIP-CD80GP mice and aggravated Graft-versus-Host disease in a xenotransplantation model. Thus, p75NTR signaling on pDCs constitutes a new and critical mechanism connecting neurotrophin signaling and immune response regulation with great therapeutic potential for a variety of immune disorders.
- 17 August 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 981
Open AccessNeurotrophin Receptor p75NTR Regulates Immune Function of Plasmacytoid Dendritic Cells
Plasmacytoid dendritic cells (pDCs) regulate innate and adaptive immunity. Neurotrophins and their receptors control the function of neuronal tissue. In addition, they have been demonstrated to be part of the immune response but little is known about the effector immune cells involved. We report, for the first time, the expression and immune-regulatory function of the low affinity neurotrophin receptor p75NTR by the antigen-presenting plasmacytoid dendritic cells (pDCs), mediated by Toll-like receptor (TLR) 9 activation and differential phosphorylation of interferon regulatory factor (IRF) 3 and 7. The modulation of p75NTR on pDCs significantly influences disease progression of asthma in an ovalbumin-induced mouse model mediated by the TLR9 signaling pathway. p75NTR activation of pDCs from patients with asthma increased allergen-specific T cell proliferation and cytokine secretion in NGF concentration dependent manner. Further, p75NTR activation of pDCs delayed the onset of autoimmune diabetes in RIP-CD80GP mice and aggravated Graft-versus-Host disease in a xenotransplantation model. Thus, p75NTR signaling on pDCs constitutes a new and critical mechanism connecting neurotrophin signaling and immune response regulation with great therapeutic potential for a variety of immune disorders.
- Open Access
- 10 May 2017
- Published by Springer Nature in Molecular and Cellular Pediatrics
- Vol. 4 (S1) , 1-9
Abstracts of the 52nd Workshop for Pediatric Research
- 10 May 2017
- Published by Springer Nature in Molecular and Cellular Pediatrics
- Vol. 4 (S1) , 1-9
Open AccessAbstracts of the 52nd Workshop for Pediatric Research